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ABSTRACT 
Metabolites derived from superoxide (02"-)  and nitric oxide 
(NO.) play an important role in antimicrobial and antitumoral 
defense, but may also harm the host. Low levels of such metabolites 
can also facilitate viral replication because of their mitogenic effects 
on cells. Most viruses grow better in proliferating cells, and indeed, 
many viruses induce in their host cell changes imilar to those seen 
early after treatment with mitogenic lectins. Influenza nd paramyxo- 
viruses activate in phagocytes the generation of superoxide by a 
mechanism involving the interaction between the viral surface glyco- 
proteins and the phagocyte's plasma membrane. Interestingly, viruses 
that activate this host defense mechanism are toxic when injected in 
the bloodstream of animals. Mice infected with influenza virus 
undergo xidative stress. In addition, a wide array of cytokines are 
formed in the lung, contributing to the systemic effects of influenza. 
Oxidative stress is seen also in chronic viral infections, such as AIDS 
and viral hepatitis. Oxidant production in viral hepatitis may con- 
tribute to the emergence of hepatocellular carcinoma,  tumor seen in 
patients after years of chronic inflammation of the liver. Antioxidants 
and agents that downregulate proinflammatory c tokines and lipid 
mediators may be a useful complement to specific antiviral drugs in 
the therapy of viral diseases. 
Index Entries: Virus; influenza; HIV; hepatitis; therapy; 
cytokines; antioxidants; nitric oxide; physiology; metabolism. 
INTRODUCTION 
The term "reactive oxygen species" (ROS) refers to an array of 
metabolites derived from molecular oxygen (02), superoxide anion radical 
(02"-) being the primary one-electron reduction product arising from 02. 
Superoxide may react with nitric oxide (NO.; formally termed "nitrogen 
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monoxide"), an easily diffusible gas derived from arginine by enzymatic 
reaction (1), or nonenzymatically by direct reduction from nitrite (2), to 
give nitroperoxide (ONOO-). Depending on the relative proportions at 
which NO. and 02"- are produced, NO. can also act as an antioxidant- 
limiting lipid peroxidation (3). ROS and nitric oxide with its unstable 
metabolites termed reactive nitrogen intermediates (RNI) are key ele- 
ments in antimicrobial nd antitumoral defense, but contribute also to 
aging and the pathogenesis of a wide array of infectious and noninfec- 
tious diseases (for a review, see 4). Less well known, but no less impor- 
tant are the multiple roles of ROS and RNI in normal physiology. For 
example, a low level of ROS is required for mitogenic cell transformation 
(5), and nitric oxide is a second messenger in brain and involved in the 
regulation of blood pressure (1). The physiological roles of ROS and RNI 
are particularly important because viruses, as intracellular parasites, 
depend on the biosynthetic mechanisms of their host cells. The link 
between the role of ROS and cell activation began to be appreciated only 
recently (for a review, see 5), much later than the virucidal effects of 
viruses (6). First indications that cell activation played a role in viral 
replication began to emerge at about he same early time, however. Thus, 
viruses were shown to grow better in lymphocytes treated with mito- 
genic lectins (7,8) and influenza viruses of the H2N2 subtype were found 
to activate lymphocytes mitogenically (9). In a study on the biochemical 
effects of Semliki Forest virus on chicken embryo cells, we noted that the 
alterations induced in mitochondria by this Togavirus were similar to 
those induced by treatment with fetal calf serum, a well-known mito- 
genic stimulus (10). Looking for evidence of activation in other cell types, 
we observed that influenza nd paramyxoviruses stimulate a respiratory 
burst in phagocytic cells. Thus, unaware at that time of the metabolic role 
of ROS in cell activation, we found that these viruses can activate an 
effector function of host defense. Activation of ROS generation by 
influenza and paramyxoviruses in the absence of antiviral antibodies 
(11,12) was of interest with respect o reports dating back to the 1940s, 
when these viruses had been shown to induce fever and even hemor- 
rhages in internal organs (13,14). The conditions for the induction of ROS 
in vitro closely resembled those required for induction of toxic effects in 
vivo, with no requirement for viral replication in either case. In fact, the 
similarity extends even further because filamentous influenza virus par- 
ticles, which are more toxic than spherical ones when injected in animals 
(15), are also more potent inducers of ROS generation i vitro (16). These 
observations led us to propose that ROS could play a role in the symp- 
toms and pathology of influenza nd other viral infections (17,18). 
This concept of viral pathogenesis was put to the test using a mouse 
model of influenza. Animals infected intranasally develop severe sys- 
temic symptoms, including a decrease in body temperature and weight 
and anorexia, and succumb at days five and six postinfection. The infec- 
tion remains restricted to the airways and lungs and is characterized by 
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massive bronchitis and pneumonia leading to decreased pO2 and 
increased pCO2 in the blood (unpublished observation). Cells lavaged 
out of the lung are primed for enhanced ROS production, as shown by 
the increase in 02"- release in response to the tumor-promoting a ent 
PMA. As an additional factor contributing to enhanced ROS production, 
the activity of xanthine oxidase, an enzyme generating 02"-, increased in 
lung homogenates. Analysis of major small molecular antioxidants (~- 
tocopherol, ascorbate, and glutathione) showed no change in the ratio of 
reduced to oxidized forms, but the concentrations of antioxidants 
decreased in the lung during infection, indicating that the antioxidant- 
buffering capacity diminishes during influenza in mice (19,20). In a more 
protracted model of influenza, Oda and coworkers howed that intra- 
venously injected pyran copolymer-conjugated superoxide dismutase 
protects against he lethal effect of influenza (21). Since pyran copoly- 
mers are well-known antiviral agents (22,23), this observation is difficult 
to interpret. Interestingly, as first demonstrated by Bykova and cowork- 
ers (24), NO. also seems to play a role in the pathogenesis of influenza, 
and indeed, it was very recently demonstrated that agents interfering 
with the formation of NO. can have a beneficial effect in murine 
influenza (25). 
The role of oxidants in influenza is complicated by several factors, 
among them the compartmental nature of infection. Even in the airways 
and lungs, not all regions are affected to the same extent, which poses 
problems with the conventional biochemical analysis of antioxidants 
because changes in the microenvironment may not be detected in tissue 
homogenates. In addition, as mentioned above, although influenza is a 
local infection of the airways and lung, disease symptoms can be severe 
both in mice and humans. In humans, influenza is characterized by 
headache, fever, and myalgia in addition to the respiratory symptoms 
related to the infection of the respiratory tract (26). Moreover, humans 
taking certain drugs that are detoxified in the liver may suffer from drug 
toxicity because of decreased liver function in the course of infection or 
after vaccination with influenza virus (27). A similar effect was observed 
also in murine influenza, with a decrease in the demethylation f 14C- 
aminopyrine (unpublished observation). The systemic effects of influenza 
may be caused by cytokines produced in the lung and released into the 
bloodstream. In mice infected with influenza virus, we demonstrated in 
the broncoalveolar l vage fluid a wide array of cytokines and lipid medi- 
ators, including tumor necrosis factor (TNF), interleukin-1 (IL-1), inter- 
feron- 7, granulocyte macrophage colony-stimulating factor (GM-CSF), 
granulocyte colony-stimulating factor (G-CSF), IL-6, and leukotriene B4 
(28). It is noteworthy that, in particular, interferons can cause influenza- 
like symptoms in humans (29). 
Although ROS are known to be virucidal (6,30), oxidants could actu- 
ally increase the titer of infectious influenza virus by a mechanism 
related to the maturation of the hemagglutinin. This viral surface glyco- 
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protein is cleaved intracellularly from a precursor protein, HAo, into its 
mature form consisting of the disulfide-linked peptides HA1 and HA2. 
Influenza virus with the immature hemagglutinin HAo may be released 
from infected cells, but is not infectious. Thus, such virus may bind to a 
cell, but HAo is unable to mediate the fusion between the viral lipid 
envelope and the endosomal membrane, leading to the release of the 
viral core into the cytoplasm. Essential for this fusion is a conformational 
change in the mature hemagglutinin, which allows the hydrophobic 
amino-terminal of HA2 to interact with the endosomal membrane. The 
proportion of infectious to noninfectious virus released from infected 
cells depends on the amino acid sequence of the hemagglutinin a d rep- 
resents an important feaure of virulence, because it determines the speed 
of viral propagation i the lung (for a review, see 31). Pulmonary surfac- 
tant contains trypsin-like protease(s) capable of cleaving HAo in HA1 
and HA2. In healthy uninfected lung, these proteases are neutralized by 
protease inhibitor (32). In bronchitis and pneumonia, phagocytes increase 
in numbers in this fluid and produce ROS (33). In a model experiment, 
we showed that NaOCI-, a highly toxic oxidant produced by phagocytic 
cells, can oxidize protease inhibitor, thereby indirectly enhancing pro- 
tease activity. We demonstrated in vitro that the viral titer under such 
conditions can increase 10,000-fold (20). This experiment may be of rele- 
vance to the observation that influenza is more severe in patients uffer- 
ing from chronic bronchitis (34), a condition known to be associated with 
enhanced protease activity in the airways. It also illustrates how the virus 
may use potentially virucidal ROS to its advantage during infection. 
Oxidants also influence the pathogenesis of other viral diseases, in 
particular infection with HIV. Humans infected with HIV are under 
chronic oxidative stress, as shown by changes in the small molecular 
antioxidants ascorbic acid, (0~-tocopherol, carotenoids, elenium, super- 
oxide dismutase, and in particular, glutathione) (for a review, see 35). 
Moreover, also pointing to oxidative stress are enhanced plasma levels of 
hydroperoxides, malondialdehyde, and clastogenic factors (36,37). In 
vitro, manipulations that result in enhanced oxidative stress enhance the 
replication of HIV (38,39), possibly via activation of NFKB, a transcrip- 
tion factor that stimulates the replication of HIV and transcription of a 
number of proinflammatory c tokine genes, among them TNF-R (40). 
The product of this gene is of particular interest, because its action on 
cells is linked to the promotion of intracellular oxidative stress, possibly 
as a result of enhanced ROS production in mitochondria (41) or by 
lipoxygenase (42). HIV may stimulate ROS production by various mech- 
anisms, including interaction of gp125 with the cell membrane (43) and 
via Tat, the transactivating protein (44). Furthermore, mycoplasmas, 
which are known to stimulate HIV replication, may also act by increas- 
ing oxidative stress, either by producing H202 (45) or by stimulating the 
respiratory burst in phagocytic ells in a fashion similar to paramyx- 
oviruses and influenza viruses (46). Finally, coinfection with mycoplas- 
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mas and HIV may result in the release of H202 from T-cells (47). The 
altered redox status seems to contribute to HIV pathogenesis in several 
ways. As the most dramatic effect, it favors the inexorable and ultimately 
fatal decrease in the number of CD4 T-cells and many of the immune 
dysfunctions reported in HIV-infected individuals (for a review, see 35). 
Much evidence suggests that death of the CD4 T-cells occurs by apopto- 
sis, a process in which oxidants have been shown to play an important 
role, and that can be prevented or slowed down by antioxidants (35,48). 
Several viruses can cause cancer by mechanisms involving onco- 
genes and tumor suppressor genes (reviewed in 49,50). In addition to 
these "classical" mechanisms, oxidant stress could also contribute to viral 
oncogenesis. In particular, several taxonomically diverse viruses cause 
hepatitis (51,52). Interestingly, only in hepatitis B virus is there convinc- 
ing evidence for a role of classical mechanisms of viral cancerogenesis 
(53). Infection with hepatitis viruses may last for years and is accompa- 
nied by inflammation, a condition associated with oxidative stress (54). 
Enhanced levels of ROS and RNI are known to be genotoxic (55). Geno- 
toxic effects may be accentuated by chronic tissue destruction leading to 
cell proliferation, because the latter results in enhanced fixation of muta- 
tions. A similar situation is encountered when potential carcinogens are 
tested at the maximum tolerated ose (55). 
Of particular interest is the formation of NO. in viral infections of 
the central nervous ystem, because NO. formed by inflammatory cells 
could interfere with the normal role of this gas as a second messenger 
in neurons (1). Possibly, formation of NO,, could explain some mental 
alterations seen in many viral infections of the brain. For example, such 
alterations occur in rabies and in particular in Borna, a viral infection 
previously known in horses and sheep, and more recently suspected 
to be a cause of some mental disorders in humans (56). In fact, the sever- 
ity of neurological signs and degree of inflammatory lesions in the 
brains of rats with Borna disease were recently shown to correlate with 
the induction of nitric oxide synthase (57), and the induction of this 
enzyme was also demonstrated in rabies, allergic encephalomyelitis (58), 
and lymphocytic choriomeningitis (59). RNI, along with ROS, could also 
be responsible for neuronal death (60), exemplifying again that these 
metabolites may have both "metabolic" and toxic effects. Furthermore, 
in some instances, NO,, production may not be induced, but the cells 
may be primed for enhanced NO. synthesis in response to secondary 
stimuli, as was observed with lymphocytic horiomeningitis (61) and 
bovine viral diarrhea viruses (62). This effect may be related to the 
immunosuppression observed uring infection in vivo. 
Finally, HIV infection (63) and HIV gp120 (64) were shown to 
enhance the production of NO. in human monocytes and exert neuro- 
toxic effects via NO. in vitro, respectively. Moreover, NO . -mediated 
toxicity of HIV and Maedi Visna virus (a lentivirus of sheep) Tat was 
demonstrated in rats after intracerebral injection (65,66). Although these 
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examples would tend to suggest that NO, may play a negative role in 
a number of viral infections, NO, can also exert antiviral effects (67,68). 
For example, NO. is thought o mediate antiviral effects of interferon-y 
against ectromelia, vaccinia, and herpes simplex viruses in mice, as 
inhibitors of iNOS-abrogated protection (69). Inhibition of viral replica- 
tion by NO, was also reported for Friend leukemia virus (70) and vesic- 
ular stomatitis virus (71). 
IS THERE A PLACE FOR ANTIOXIDANTS 
IN VIRAL DISEASES? 
As discussed above, there is now much evidence that oxidants play 
a complex role in viral diseases, starting from influences on host cell 
metabolism and viral replication and extending to desired inactivating 
effects on viruses and less desired toxic effects on host tissue. Use of 
antioxidants in the therapy of viral diseases can therefore be expected to 
act at many different levels. Although for reasons outlined above it has 
remained ifficult to demonstrate changes in the redox status of small 
molecular antioxidants, recent observations indicate that clear deficits in 
antioxidants can have quite dramatic effects on the outcome of viral 
infections. Most remarkable is the observation that mice made deficient 
in selenium and vitamin E may be killed by Coxsackie virus strains, 
which are harmless in selenium-sufficient animals. The unexpected 
observation that a number of animals inoculated with an attenuated 
strain produced a virulent strain capable of also killing animals ufficient 
in selenium and vitamin E suggests that the antioxidant s atus of a host 
may even influence viral evolution by as yet unknown mechanisms 
(72-74). Antioxidants, particularly when given in a blend and at propor- 
tions present in a balanced iet of fruits and vegetables, are not toxic, 
and no untoward effects are to be expected from their use as a support- 
ive adjunct o conventional therapy in viral diseases. Whether this is also 
true for synthetic antioxidants, like BHT, is less clear, as indicated by the 
observation that this antioxidant prevented the immune response of 
chickens to Newcastle disease virus. Interestingly, BHT also prevented 
the lethal effect of this virus in birds (75). 
A therapy should also target additional mechanisms that contribute 
to the symptoms and pathology of viral diseases, such as certain 
cytokines, NO,, and lipid mediators. Of course, one could argue that this 
approach fails to interfere directly with the replication of the virus, and 
would therefore simply extend the old-fashioned "symptomatic" therapy 
that is based on agents, such as aspirin. This criticism fails to take into 
account hat: 
1. In acute viral infections, symptoms lag behind the maxi- 
mum phase of viral replication; 
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2. With rare exceptions, antiviral drugs that match the speci- 
ficity and, in particular, the low host toxicity of antibiotics 
used to combat bacteria re still not available; and 
3. Such a therapy would have a sound scientific basis, because 
it rests on understanding of the mechanisms causing disease 
symptoms and pathology. 
Finally, one could also argue that, irrespective how old-fashioned a ther- 
apy based on a simple drug such as aspirin may be, it has shown bene- 
ficial effects in millions of humans suffering from the common cold. 
Surely, such an approach would not make unneccessary a further search 
for better antivirals, particularly with severe infections, such as hepatitis 
or encephalitis. 
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